 |
| |
Arana Therapeutics Limited (Arana) is engaged in the commercialization of research, development, investment in, and licensing of technology, and the formulation, manufacture and marketing of protein-based products for the pharmaceutical industry. ART621 is a new type of therapeutic protein, which incorporates a domain antibody (dAb) and is the first compound incorporating a domain antibody to be used in human trials. PMX53 is a complement 5a (C5a) inhibitor. Arana has developed a new antibody candidate, ART 123 targeting the inflammatory diseases. ART010 is aimed at treating the side-effects of cancer known as cancer-related bone loss. ART104 is an antibody in development for the treatment of colorectal cancer. ART150 is an antibody under development for the treatment of lung cancer and melanoma. Arana has a protein engineering technology platform that incorporates the Company's Superhumanisation, Synhumanisation and EvoGene technologies.
Arana Therapeutics Limited - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Summary
Arana Therapeutics Limited (Arana), a biopharmaceutical company, is engaged in the research and development of new generation products for the treatment of inflammatory diseases and cancer. The company also involves in the research, development, manufacturing and marketing of protein based products for the pharmaceutical industry. The company is headquartered in Sydney at New South Wales, Australia. In May 2009, Cephalon, Inc. acquired over 50% of controlling interest in Arena. In March 2009, Arena successfully completed phase II clinical trial studies of ART621 for stable plaque psoriasis.
The Arana Therapeutics Limited - Pharmaceuticals & Healthcare - Deals and Alliances Profile is an essential source for company data and information. The profile examines the company's key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy as well as highlighting the company's major recent financial deals.
Scope
- Provides key company information for business intelligence needs
- Gives information on the company's major recent financial deals including Mergers and Acquisitions, asset transactions, PE/VC deals, equity offerings, debt offerings and partnerships.
- Data is supplemented with details on the company's history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement.
Reasons to buy
- A quick "one-stop-shop" to understand the company.
- Support sales activities by understanding your customers' businesses.
- Qualify prospective partners and suppliers.
- Understand and respond to your competitors' business structure, strategy and prospects through.
- Understanding the key deals which have shaped the company.
Arana Therapeutics Limited - Pharmaceuticals & Healthcare - Deals and Alliances Profile: http://www.companiesandmarkets.com/r.ashx?id=QUH2STKN8166552
|
—
